Who are M-CENK's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): [68Ga]Ga-PentixaFor, TBI-1301, CHS-1420, TAK-667, SHR-1314, RNF.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/m-cenk.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

M-CENK — Competitive Intelligence Brief

M-CENK (M-CENK) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Checkpoint inhibitor. Area: Oncology.

phase 2 Checkpoint inhibitor CD47 Oncology Biologic Live · refreshed every 30 min

Target snapshot

M-CENK (M-CENK) — ImmunityBio, Inc.. M-CENK is a cancer immunotherapy that targets the CD47/SIRPα axis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
M-CENK TARGET	M-CENK	ImmunityBio, Inc.	phase 2	Checkpoint inhibitor	CD47
[68Ga]Ga-PentixaFor	[68Ga]Ga-PentixaFor	Nantes University Hospital	phase 3	Radiopharmaceutical	CD47
TBI-1301	TBI-1301	Takara Bio Inc.	phase 3	CD47 antibody	CD47
CHS-1420	CHS-1420	Coherus Oncology, Inc.	phase 3	Bispecific antibody	CD47 and CD40
TAK-667	TAK-667	Takeda	phase 3	CD47 antibody	CD47
SHR-1314	SHR-1314	Jiangsu HengRui Medicine Co., Ltd.	phase 3	CD47/SIRPα inhibitor	CD47/SIRPα axis
RNF	RNF	Merck KGaA, Darmstadt, Germany	phase 3	CD47/SIRPα inhibitor	CD47

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Checkpoint inhibitor class)

ImmunityBio, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). M-CENK — Competitive Intelligence Brief. https://druglandscape.com/ci/m-cenk. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab